ライフサイエンスコーパス: varicella-zoster virus

1 2, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus.

2 erpes simplex virus and 8 patients (38%) had varicella zoster virus.

3 ese is also activated by the closely related varicella zoster virus.

4 ew mutations or recombination with wild-type Varicella zoster virus.

5 losely related to herpes simplex viruses and varicella-zoster virus.

6 G synthesis, and elevated antibody titers to varicella-zoster virus.

7 d, for example, in relation to pertussis and varicella-zoster virus.

8 pathogens herpes simplex viruses 1 and 2 and varicella-zoster virus.

9 ation were detected in OPV, mumps virus, and varicella-zoster virus.

10 uses herpes simplex virus type 1 (HSV-1) and varicella-zoster virus.

11 1), P. jirovecii pneumonia (1.77; .42-7.47), varicella-zoster virus (1.51; .71-3.22), as well as over

12 -Barr virus, 3%; herpes simplex virus 1, 3%; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex

13 d 9 with herpes simplex virus (8.8%), 5 with varicella-zoster virus (4.9%), 27 with cytomegalovirus (

14 CF; human cytomegalovirus (HCMV) 11% in GCF; varicella zoster virus 6% in saliva and 3% in GCF; of hu

15 For herpes simplex virus, varicella zoster virus and cytomegalovirus, these advanc

16 RN, PCR-positive for herpes simplex virus or varicella zoster virus and evaluated between January 200

17 genes of both herpes simplex virus (HSV) and varicella zoster virus and functions, in part, by coupli

18 beyond CMV to other herpes viruses, such as varicella zoster virus and possibly Epstein-Barr virus.

19 ld decrease external boosting of immunity to varicella zoster virus and thereby increase incidence of

20 cropsy of two monkeys inoculated with simian varicella-zoster virus and euthanized 117 days later.

21 y, other human-restricted viruses.IMPORTANCE Varicella-zoster virus and human cytomegalovirus infect

22 ia in adults includes common agents, such as varicella-zoster virus and influenza virus, as well as r

23 finding associated with uveitis secondary to varicella-zoster virus and Toxoplasma gondii coinfection

24 s of anterior uveitis in his left eye due to varicella-zoster virus and Toxoplasma gondii coinfection

25 ty of herpes simplex virus, cytomegalovirus, varicella zoster virus, and Epstein-Barr virus in our po

26 Herpes simplex virus, varicella zoster virus, and pseudorabies virus are neuro

27 2, human herpesvirus 6, human parechovirus, varicella-zoster virus, and Cryptococcus neoformans/Cryp

28 Findings from skin biopsy, viral culture for varicella-zoster virus, and skin prick test to common fo

29 Varicella-zoster virus antigen was found in 45 of 70 GCA

30 Varicella-zoster virus antigen was frequently found in p

31 e whether herpes zoster antigen (also called varicella-zoster virus antigen) was detectable in tempor

32 gical boosting, through which reexposures to varicella-zoster virus are thought to reduce the individ

33 nstrate that childhood infections, including varicella zoster virus, are associated with an increased

34 h HLA-B27-associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778] pg/mL) uv

35 for other infections (herpes simplex virus, varicella zoster virus, bacterial and fungal infections)

36 itis (AU), owing to either herpes simplex or varicella zoster virus, by using the Standardization of

37 clonal antibodies against a major antigen of varicella-zoster virus called gE.

38 MPORTANCE Herpes simplex viruses 1 and 2 and varicella-zoster virus cause significant morbidity and m

39 We compared varicella-zoster virus cell-mediated immunity (VZV-CMI)

40 se encephalitis virus, herpes simplex virus, varicella zoster virus, cytomegalovirus, dengue virus an

41 (HSV) and other alphaherpesviruses, such as varicella-zoster virus, depend upon the capacity to navi

42 ES by the corresponding region from ORF61 of varicella-zoster virus did not rescue ND10 fusion.

43 (as determined by testing lesions swabs for varicella zoster virus DNA by polymerase chain reaction)

44 ence of confirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from

45 Varicella zoster virus DNA was detected 2 months after t

46 Varicella zoster virus encephalitis was infrequent follo

47 th HSE (p.Leu297Val) and 1 in a patient with varicella-zoster virus encephalitis (p.Leu199Phe).

48 the phenotypic spectrum of TLR3 mutations to varicella-zoster virus encephalitis and support the role

49 Varicella zoster virus encodes an immediate-early (IE) p

50 deficiency virus (HIV)-herpes simplex virus, varicella zoster virus, Epstein-Barr virus (EBV), and cy

51 ZVL and, together with baseline immunity to varicella-zoster virus, explains the effect of age on th

52 rpes zoster is a common late complication of varicella-zoster virus exposure and can be further compl

53 hus, a 30-h delay after death did not affect varicella-zoster virus expression in latently infected g

54 Studies of varicella-zoster virus gene expression during latency re

55 The varicella-zoster virus geometric mean titer (GMT) and ge

56 were randomized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant Sy

57 ve (at months 0, 1, 3) three doses of 50 mug varicella-zoster virus glycoprotein E (gE) adjuvanted wi

58 An adjuvanted varicella-zoster virus glycoprotein E (gE) subunit vacci

59 ubjects received 3 doses of HZ/su (50 microg varicella-zoster virus glycoprotein E [gE] combined with

60 g older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adju

61 zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with su

62 equences of wild-type and vaccine strains of varicella-zoster virus have been published and listed in

63 erritin levels were highest in patients with varicella-zoster virus, hepatitis, or malaria (median, 1

64 megalovirus (HR, 3.98 [95% CI, 1.40-11.26]), varicella zoster virus (HR, 1.49 [95% CI, 1.18-1.89]), h

65 ytomegalovirus [CMV], herpes simplex I/II or varicella zoster virus [HSV/VZV], blood stream infection

66 gnificant members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epste

67 rveillance, combined with information from a Varicella Zoster Virus Identification Program, which use

68 ogic modulators restores immune responses to varicella-zoster virus in vaccinees.

69 highly dependent on the host cell, we tested varicella zoster virus-infected cell lysates and clinica

70 cation) were associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95

71 contact dermatitis, infectious folliculitis, varicella zoster virus infection, fixed drug eruption, a

72 processes, including ubiquitin clearance and Varicella Zoster Virus infection.

73 or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more we

74 erties that may favor reactivation of latent varicella-zoster virus infection.

75 nd increased susceptibility to bacterial and varicella zoster virus infections.

76 While varicella-zoster virus is also insensitive to interferon

77 regulate infection of host cells.IMPORTANCE Varicella-zoster virus is an important human pathogen, w

78 Because features of varicella-zoster virus latency are similar in primate an

79 The varicella-zoster virus major transactivator, IE62, conta

80 One patient with varicella zoster virus meningitis and acute GVHD had iC9

81 Mumps, measles, rubella, and varicella-zoster viruses (MMRV) may cause severe infecti

82 Available varicella-zoster virus models can be classified in 3 mai

83 es (parechovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyss

84 = 60), followed by tuberculosis (n = 8) and varicella zoster virus (n = 7).

85 e fills a notable gap in our knowledge about varicella zoster virus neuronal transportation.

86 ilar function in human herpesviruses such as varicella-zoster virus or herpes simplex viruses.

87 -coinfected children and were independent of varicella-zoster virus or herpes-simplex virus 1 coinfec

88 derate quality showed an association between varicella zoster virus reactivation (ophthalmic zoster)

89 Because there is no good animal model of varicella zoster virus reactivation from latency, this e

90 genes, Treponema pallidium, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and He

91 Among the 131 live births to varicella-zoster virus-seronegative women, there was no

92 nation that elicited an exceptionally strong varicella zoster virus-specific B-cell and CD8 T-cell re

93 in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to va

94 1, CTLA-4, and TIM-3, whereas <2% of CMV- or varicella-zoster virus-specific CD4(+) T cells expressed

95 the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA)

96 ng heat-inactivated or replication-defective varicella-zoster virus to prevent HZ in immunocompromise

97 The continued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-z

98 The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in

99 s HSV1 and HSV2 (also termed HHV1 and HHV2), varicella zoster virus (VZV or HHV3), EBV (HHV4), cytome

100 tients showed a decreased ability to control varicella zoster virus (VZV) and Epstein-Barr virus (EBV

101 Varicella zoster virus (VZV) and the two herpes simplex

102 Varicella zoster virus (VZV) antibody titers (measured b

103 Varicella zoster virus (VZV) antigen was found in all of

104 Vasculopathies caused by varicella zoster virus (VZV) are indicative of a product

105 CMV and varicella zoster virus (VZV) are significant causes of m

106 response biomarkers measuring antibodies to varicella zoster virus (VZV) by glycoprotein-based enzym

107 lex virus types 1 (HSV-1) and 2 (HSV-2), and varicella zoster virus (VZV) by weekly polymerase chain

108 se of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a

109 , or no history of zoster (group 3) revealed varicella zoster virus (VZV) DNA in saliva samples from

110 rs who were immunized with Zostavax revealed varicella zoster virus (VZV) DNA in swabs of skin inocul

111 Herpesvirions and varicella zoster virus (VZV) DNA were recently reported

112 Varicella zoster virus (VZV) establishes latency in dors

113 Varicella zoster virus (VZV) establishes lifelong persis

114 as an alternative to sampling of rashes for varicella zoster virus (VZV) genotyping and further char

115 s positive for herpes simplex virus (HSV) or varicella zoster virus (VZV) in 79% to 100% of cases of

116 Clinical reports observe the reactivation of varicella zoster virus (VZV) in people who have recovere

117 Reactivation of the varicella zoster virus (VZV) increases during aging.

118 Varicella zoster virus (VZV) infections are a relevant c

119 virus (CMV), herpes simplex virus (HSV), and varicella zoster virus (VZV) infections were monitored i

120 Varicella zoster virus (VZV) is a neurotropic alphaherpe

121 Varicella zoster virus (VZV) is a skin-tropic virus that

122 As) from patients with giant cell arteritis, varicella zoster virus (VZV) is seen in perineurial cell

123 Varicella zoster virus (VZV) is the causative agent of c

124 Varicella Zoster Virus (VZV) is the causative agent of v

125 Varicella zoster virus (VZV) is the etiological agent of

126 s" postulates that reexposure to circulating varicella zoster virus (VZV) over the life span inhibits

127 Varicella zoster virus (VZV) reactivation results in zos

128 An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being de

129 zoster (HZ) cases may play a larger role in varicella zoster virus (VZV) transmission.

130 Varicella zoster virus (VZV) typically causes chickenpox

131 ne responses to a high-titer live attenuated varicella zoster virus (VZV) vaccine (zoster vaccine), w

132 te the efficacy and safety of an inactivated varicella zoster virus (VZV) vaccine for herpes zoster p

133 Since the introduction of live attenuated varicella zoster virus (VZV) vaccine in 1995 there has b

134 s, granulomatous aortitis, and intracerebral varicella zoster virus (VZV) vasculopathy.

135 lovirus (CMV), Epstein-Barr virus (EBV), and varicella zoster virus (VZV) was determined in crewmembe

136 IL-10 and immunity to varicella zoster virus (VZV) were measured at baseline a

137 cytomegalovirus, herpes simplex virus (HSV), varicella zoster virus (VZV), and rubella.

138 portion of HZ cases caused by vaccine-strain varicella zoster virus (VZV), assessed the positive pred

139 c primers to detect DNA from JC virus (JCV), varicella zoster virus (VZV), cytomegalovirus (CMV), Eps

140 d were hepatitis A (HAV), hepatitis B (HBV), varicella zoster virus (VZV), measles, and mumps.

141 on childhood disease, chicken pox, caused by varicella zoster virus (VZV), over an 11-y period.

142 erpesviruses, herpes simplex virus (HSV) and varicella zoster virus (VZV), results in the rapid accum

143 immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereaft

144 Boost of varicella zoster virus (VZV)-specific cellular immunity

145 We investigated the relationship between varicella zoster virus (VZV)-specific memory CD4(+) T ce

146 virus type 1 (HSV-1) and type 2 (HSV-2) and varicella zoster virus (VZV)-was determined in autonomic

147 1 and 2 and the sequence-divergent pathogen varicella zoster virus (VZV).

148 ompromised individuals after reactivation of varicella zoster virus (VZV).

149 n pathogens herpes simplex viruses (HSV) and varicella zoster virus (VZV).

150 ses with age, which leads to reactivation of varicella zoster virus (VZV).

151 Varicella-zoster virus (VZV) activates the phosphatidyli

152 SV functioned as a monopartite NLS, while in varicella-zoster virus (VZV) activity required an adjace

153 are the main architectural contrasts between varicella-zoster virus (VZV) and herpes simplex virus (H

154 d the Us9 homologs from two human pathogens, varicella-zoster virus (VZV) and herpes simplex virus ty

155 Intraocular varicella-zoster virus (VZV) and HSV type 1 (HSV-1) infe

156 The herpesviruses varicella-zoster virus (VZV) and human cytomegalovirus (

157 herpes simpex virus 1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV) and human herpesvirus 8 (HH

158 reactivation of herpesviruses, most commonly varicella-zoster virus (VZV) and pseudorabies virus (PRV

159 simplex virus type 1 (HSV-1) is conserved in varicella-zoster virus (VZV) and pseudorabies virus (PRV

160 ype 1 (EHV-1), pseudorabies virus (PRV), and varicella-zoster virus (VZV) and their subsequent functi

161 Infections with varicella-zoster virus (VZV) are associated with a range

162 gument proteins encoded by ORF11 and ORF9 of varicella-zoster virus (VZV) are conserved among all alp

163 Infection of human neurons in vitro with varicella-zoster virus (VZV) at a low multiplicity of in

164 y, IDE has been proposed as the receptor for varicella-zoster virus (VZV) attachment.

165 Varicella-zoster virus (VZV) causes chicken pox and shin

166 Varicella-zoster virus (VZV) causes chickenpox and react

167 highly infectious, human-restricted pathogen varicella-zoster virus (VZV) causes chickenpox and shing

168 ating VZV from clinical specimens.IMPORTANCE Varicella-zoster virus (VZV) causes chickenpox and shing

169 Varicella-zoster virus (VZV) causes chickenpox upon prim

170 ies for treatment of VZV diseases.IMPORTANCE Varicella-zoster virus (VZV) causes herpes zoster, a maj

171 Varicella-zoster virus (VZV) causes varicella and establ

172 Varicella-zoster virus (VZV) characteristically forms mu

173 We studied a patient with varicella-zoster virus (VZV) CNS vasculopathy and as par

174 y throughout the study and were analyzed for varicella-zoster virus (VZV) DNA by use of both qualitat

175 Wild-type varicella-zoster virus (VZV) DNA was identified in all 3

176 In this report, we investigated varicella-zoster virus (VZV) egress in a cell line from

177 Herein we describe an episode of focal varicella-zoster virus (VZV) encephalitis in a healthy y

178 The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a lifelong late

179 Varicella-zoster virus (VZV) establishes latency in huma

180 Varicella-zoster virus (VZV) establishes lifelong neuron

181 ts had similar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measu

182 When grown in cultured cells, varicella-zoster virus (VZV) forms many aberrant light p

183 Information about varicella-zoster virus (VZV) gB is limited, but homology

184 tive target for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV) has infected over 90% of pe

185 Mechanisms of neuronal infection by varicella-zoster virus (VZV) have been challenging to st

186 (EBV) EB2, herpes simplex virus (HSV) ICP27, varicella-zoster virus (VZV) IE4/ORF4, and cytomegalovir

187 The varicella-zoster virus (VZV) IE62 protein is the major t

188 Varicella-zoster virus (VZV) immediate-early 63 protein

189 nses in the bone marrow.IMPORTANCE Childhood varicella-zoster virus (VZV) immunization induces immune

190 ects immediate-early protein IE63 encoded by varicella-zoster virus (VZV) in the cytoplasm of product

191 sensitivity to detect antibody responses to varicella-zoster virus (VZV) in vaccinated individuals,

192 Varicella-zoster virus (VZV) induces apoptosis in human

193 Previous studies have demonstrated that varicella-zoster virus (VZV) infection activates ERK1/2,

194 Varicella-zoster virus (VZV) infection causes varicella,

195 Primary varicella-zoster virus (VZV) infection in humans produce

196 Varicella-zoster virus (VZV) infection is usually mild i

197 Transcriptional changes following varicella-zoster virus (VZV) infection of cultured human

198 acaques (RMs) recapitulates the hallmarks of varicella-zoster virus (VZV) infection of humans, includ

199 Varicella-zoster virus (VZV) infection provides a valuab

200 extensively studied the role of autophagy in varicella-zoster virus (VZV) infection, and have observe

201 ent infant with concurrent primary wild-type varicella-zoster virus (VZV) infection, in whom chickenp

202 Varicella-zoster virus (VZV) infections increasingly are

203 Varicella-zoster virus (VZV) is a common pathogen that c

204 Varicella-zoster virus (VZV) is a highly contagious agen

205 Varicella-zoster virus (VZV) is a highly neurotropic vir

206 Varicella-zoster virus (VZV) is a human alpha-herpesviru

207 Varicella-zoster virus (VZV) is a human alphaherpesvirus

208 Varicella-zoster virus (VZV) is a human neurotropic alph

209 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV) is a major viral trans-acti

210 Varicella-zoster virus (VZV) is a medically important hu

211 Varicella-zoster virus (VZV) is a neurotropic alphaherpe

212 Varicella-zoster virus (VZV) is a ubiquitous pathogen th

213 Varicella-zoster virus (VZV) is a ubiquitous, highly cel

214 Varicella-zoster virus (VZV) is an alphaherpesvirus that

215 Varicella-zoster virus (VZV) is an alphaherpesvirus that

216 Varicella-zoster virus (VZV) is an alphaherpesvirus that

217 Varicella-zoster virus (VZV) is an alphaherpesvirus that

218 Varicella-zoster virus (VZV) is an extremely cell-associ

219 e major immediate early 62 (IE62) protein of varicella-zoster virus (VZV) is delivered to newly infec

220 Varicella-zoster virus (VZV) is highly cell associated w

221 mary infection, latency, and reactivation by varicella-zoster virus (VZV) is incompletely understood.

222 Varicella-zoster virus (VZV) is one of the most common a

223 Varicella-zoster virus (VZV) is renowned for its low tit

224 Varicella-zoster virus (VZV) is renowned for its very lo

225 Varicella-zoster virus (VZV) is the alphaherpesvirus tha

226 Varicella-zoster virus (VZV) is the causative agent of b

227 Varicella-zoster virus (VZV) is the causative agent of c

228 Varicella-zoster virus (VZV) is the etiological agent of

229 Varicella-zoster virus (VZV) is under consideration as a

230 We report a case of AIDS presenting as varicella-zoster virus (VZV) meningomyeloradiculitis ass

231 f herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) on 695 consecutive cutaneou

232 Varicella-zoster virus (VZV) open reading frame (ORF) 63

233 The varicella-zoster virus (VZV) open reading frame 54 (ORF5

234 Varicella-zoster virus (VZV) open reading frame 61 (ORF6

235 Three loci in varicella-zoster virus (VZV) open reading frame 62 (ORF6

236 f transcripts corresponding to all 68 unique varicella-zoster virus (VZV) open reading frames (ORFs)

237 The varicella-zoster virus (VZV) ORF61 protein is necessary

238 The architecture of the varicella-zoster virus (VZV) origin of DNA replication (

239 The varicella-zoster virus (VZV) origin of DNA replication (

240 In this report, we show that ORF61p, the varicella-zoster virus (VZV) ortholog of ICP0, does not

241 ced syncytium formation, a characteristic of varicella-zoster virus (VZV) pathology in skin and senso

242 this minireview is to provide an overview of varicella-zoster virus (VZV) phylogenetics and phylogeog

243 Analyses of varicella-zoster virus (VZV) protein expression during l

244 ORF66p, a virion-associated varicella-zoster virus (VZV) protein, is a member of a c

245 IMPORTANCE The neurological damage caused by varicella-zoster virus (VZV) reactivation is commonly ma

246 Varicella-zoster virus (VZV) T-cell responses by interfe

247 Varicella-zoster virus (VZV) T-cell-mediated immunity (V

248 The varicella-zoster virus (VZV) terminase components (pORF2

249 r herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) to the BD Max system by usi

250 Studies of varicella-zoster virus (VZV) tropism for T cells support

251 Varicella-zoster virus (VZV) vaccine appears to be safe

252 Although a varicella-zoster virus (VZV) vaccine has been used for m

253 ldhood immunization with the live-attenuated varicella-zoster virus (VZV) vaccine induces protective

254 of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine.

255 75 years) immunized with the live-attenuated varicella-zoster virus (VZV) vaccine.

256 Varicella-zoster virus (VZV) vasculopathy produces strok

257 ent of active lesions (e.g. HSV-1, HSV-2 and varicella-zoster virus (VZV)).

258 Varicella-zoster virus (VZV), a double-stranded DNA alph

259 igated during the entire infectious cycle of varicella-zoster virus (VZV), a human herpesvirus.

260 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV), a major viral trans-activa

261 Primary infection with varicella-zoster virus (VZV), a neurotropic alphaherpesv

262 Regulation of gene transcription in varicella-zoster virus (VZV), a ubiquitous human neurotr

263 1) and pseudorabies virus (PRV) and ORF66 in varicella-zoster virus (VZV), affects several viral and

264 Here we report that varicella-zoster virus (VZV), an alphaherpesvirus that i

265 pear healthy at 2 weeks after infection with varicella-zoster virus (VZV), and the cell culture mediu

266 ovirus, herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), and West Nile virus (WNV).

267 sviruses, herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), confirmed the expression o

268 ults for herpes simplex virus 1/2 (HSV-1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV), or

269 icella virus (SVV), the counterpart of human varicella-zoster virus (VZV), developed primary infectio

270 In this study, quantitative PCR detected varicella-zoster virus (VZV), herpes simplex virus 1 (HS

271 Varicella-zoster virus (VZV), in both wild-type and live

272 ing the medically important alphaherpesvirus varicella-zoster virus (VZV), induce fusion of the virio

273 Varicella-zoster virus (VZV), of the family Alphaherpesv

274 showed cytopathic changes, but HSV-1, unlike varicella-zoster virus (VZV), only rarely infected satel

275 Like varicella-zoster virus (VZV), simian varicella virus (SV

276 nation was more likely to identify wild-type varicella-zoster virus (VZV), whereas the presence of Ok

277 Thus, we examined whether varicella-zoster virus (VZV)-infected cells produce amyl

278 In varicella-zoster virus (VZV)-infected primary human brai

279 the risk of herpes zoster (HZ), we compared varicella-zoster virus (VZV)-specific and nonspecific T-

280 Varicella-zoster virus (VZV)-specific cell-mediated immu

281 n association with an age-related decline in varicella-zoster virus (VZV)-specific cell-mediated immu

282 udy were to evaluate the association between varicella-zoster virus (VZV)-specific humoral and cell-m

283 To measure varicella-zoster virus (VZV)-specific immune responses u

284 ssays and flow cytometry, we determined that varicella-zoster virus (VZV)-specific peak T helper 1 (V

285 itive GCA is associated with TA infection by varicella-zoster virus (VZV).

286 rus (CMV), herpes simplex viruses (HSV), and varicella-zoster virus (VZV).

287 rpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV).

288 ly recognized component of the life cycle of varicella-zoster virus (VZV).

289 lication that can occur with reactivation of varicella-zoster virus (VZV).

290 potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV).

291 Our work has shown that varicella-zoster virus (VZV; also called human herpesvir

292 None have yet been reported in varicella-zoster virus (VZV; also known as human herpesv

293 Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a common conditi

294 onal and pathogen-specific stimulation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

295 virus 1 [HSV-1], HSV-2, JC virus [JCV], and varicella-zoster virus [VZV]).

296 ion (PCR) for herpes simplex virus (HSV) and varicella zoster virus was done in 237 (69%) and 82 (24%

297 HHV-1 and Varicella-Zoster virus were detected only twice and HHV-

298 ty for CMV, EBV, herpes-simplex virus 1, and varicella-zoster virus were studied in 1079 6-year-old c

299 ncing to identify nosocomial transmission of varicella-zoster virus with fatal outcome.

300 nate gene activation by live yellow-fever or varicella-zoster virus (YFV/VZV) vaccines was more suspe